Financials
Financial year 2025
Bex Pharma from Buggenhout, company number BE0681988489, closed financial year 2025 with a result of € 30,226 after tax. For that financial year Bex Pharma recorded a gross margin of € 84,938 and equity of € 319,718. Compared with financial year 2024, the result moved from € 81,439 to € 30,226. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 31, 2026.
€ 319,718
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 30,226
▼ 63% vs 2024
Profit after tax over the fiscal year.
€ 31,035
▼ 79% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 39,457 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 42,364
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 602,804
▼ 11% vs 2024
€ 71,461 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 142
▼ 82% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 14,005
▲ 9% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 89,705 | € 76,968 | € 103,307 | € 84,938 | ▼ 18% |
| Profit after taxes | € 127,249 | € 48,454 | € 81,439 | € 30,226 | ▼ 63% |
| Equity | € 271,008 | € 286,034 | € 328,949 | € 319,718 | ▼ 3% |
| Total debts | € 876,791 | € 879,872 | € 906,460 | € 816,976 | ▼ 10% |
| Cash | € 5,647 | - | € 144,579 | € 31,035 | ▼ 79% |
| Retained profit | € 258,608 | € 267,484 | € 310,399 | € 301,168 | ▼ 3% |
| Dividend | € 50,000 | € 39,578 | € 38,524 | € 39,457 | ▲ 2% |
| Bank debt | € 762,942 | € 699,734 | € 674,661 | € 602,804 | ▼ 11% |
| Balance sheet total | € 1,147,799 | € 1,165,906 | € 1,235,409 | € 1,136,694 | ▼ 8% |
Key figures of Bex Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Bex Pharma?
What happened at Bex Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 30,226 (▼ 63% vs 2024). Source: NBB ↗
- New establishment in Buggenhout. KBO
- Start of the company according to the CBE. KBO
- Liesbet Heyvaert became a director. NBB
In short
From € 127,249 profit in 2022 to € 30,226 profit in 2025.
Paid € 93,611 in corporate taxes since 2022.
Best year ever: 2022, with € 127,249 profit.
Paid out € 167,559 in dividends to the owners in total.
Management
Behind Bex Pharma is Liesbet Heyvaert. It owns 45% of Opniphar itself.
Directors
According to the 2025 annual accounts
since 2017
Establishments
Establishment units
Physical locations of this company
Broekstraat 28
9255 Buggenhout
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0681.988.489
- VAT number
- BE 0681.988.489
- Registered office
- Broekstraat 28, 9255 Buggenhout
- Names & denominations
- Bex Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 October 2017
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering